Skip to main content

5 Result(s)

within Maiwenn J. Al Remove this filter Health Administration Remove this filter

and
Your search also matched 6 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis

Include preview-only content

  1. Article

    Open Access

    Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

    The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with my...

    Hedwig M. Blommestein, Nigel Armstrong, Steve Ryder, Sohan Deshpande… in PharmacoEconomics (2016)

    Download PDF (435 KB) View Article

  2. Article

    Open Access

    Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza®, Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the dr...

    Nasuh C. Büyükkaramikli, Hedwig M. Blommestein, Rob Riemsma… in PharmacoEconomics (2017)

    Download PDF (453 KB) View Article

  3. Article

    Open Access

    Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid®, Celgene) to submit evid...

    Nasuh C. Büyükkaramikli, Saskia de Groot, Debra Fayter, Robert Wolff… in PharmacoEconomics (2018)

    Download PDF (529 KB) View Article

  4. Article

    Open Access

    Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence, as part of the institute’s single technology appraisal process, invited the manufacturer of ribociclib (Kisqali®, Novartis) to submit evidence regarding the ...

    Nasuh C. Büyükkaramikli, Saskia de Groot, Rob Riemsma, Debra Fayter… in PharmacoEconomics (2019)

    Download PDF (1072 KB) View Article

  5. Article

    Open Access

    Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia

    The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assess...

    Rick A. Vreman, Joost W. Geenen… in Applied Health Economics and Health Policy (2019)

    Download PDF (1079 KB) View Article